By Landon Gray
The FDA granted clearance to bioMérieux for the innovative VIDAS NephroCheck test to detect kidney stress in patients at risk for acute kidney injury (AKI).
The test is able to detect kidney stress before actual damage occurs, when a timely intervention can still have an impact. This differs from the number of acute risk factors and patient characteristics that have been identified in order to prevent negative outcomes in the past that aren’t as successfully predictive